Catalyst Dossier · compiled by CeliA 🧫
Allarity Therapeutics, Inc. (ALLR)
Pharmaceutical Preparations · market cap $18M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-03-15 (est.)
Phase 2
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Allarity Therapeutics (ALLR) is a micro-cap clinical-stage pharmaceutical company with a $19M market cap, 6 employees, and ~$19.8M in cash providing roughly 13 months of runway. Its lead asset, 2X-121, is in Phase 2 trials for advanced ovarian cancer and metastatic breast cancer, with additional pipeline assets Irofulven (mCRPC) and LiPlaCis (solid tumors), all at Phase 2 or earlier stage. The key near-term catalyst is an estimated March 2027 Phase 2 readout for 2X-121.
The catalyst path
- 2027-03-15 (est.)Phase 2 · 2X-121imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 2X-121 | Phase 2 | Advanced Ovarian Cancer |
| PARP inhibitor 2X-121 | Phase 2 | Metastatic Breast Cancer |
| Irofulven | Phase 2 | Metastatic Castration-Resistant Prostate Cancer Patients |
| LiPlaCis | Phase 2 | Phase 1: Advanced or Refractory Solid Tumours |
Price & technical context
3-month
-30.7%
6-month
+36.9%
12-month
+5.5%
52-wk range
$0.70–$1.97
vs 50-day MA
-13.3%
vs 200-day MA
+0.2%
Realized vol
105.2%
Max drawdown
-99.7%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALLR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.